Ipsen【IPN】銘柄情報

	リアルタイム株価	レベル2
Forex

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

109.70

買値

109.70

売値

109.80

出来高

3,802

109.60 日の範囲 110.30

99.70 52 週間の範囲 126.70

時価総額

8.999B

前日終値

109.50

始値

109.60

時刻

109.7

最終取引時間

20:30:49

財務取引量

VWAP

平均取引量 (3 か月)

62,705

発行済株式数

82,029,421

配当利回り

1.09%

PER

14.02

1 株当たり利益 (EPS)

7.86

歳入

3.37B

純利益

644.4M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.ipsen.com

本社

Boulogne-billancourt, Hauts-de-seine, Fra

設立

Ipsen SA is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker IPN. The last closing price for Ipsen was 109.50 €. Over the last year, Ipsen shares have traded in a share price range of 99.70 € to 126.70 €.

Ipsen currently has 82,029,421 shares in issue. The market capitalisation of Ipsen is 8.98 € billion. Ipsen has a price to earnings ratio (PE ratio) of 14.02.

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG Ipsen met en avant...

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS Ipsen presents 3 late-breaking presentations and 8 abstracts across...

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today...

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus Ipsen presents 3 late-breaking presentations and 8 abstracts...

Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit

Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit...

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September...

Ipsen - Octobre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Ipsen - Octobre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de...

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights...

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global...

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	2	1.85701021356	107.7	111.5	107	78683	110.3211416	DE
4	-2.9	-2.57548845471	112.6	113.7	105.5	63228	110.00895688	DE
12	0.5	0.457875457875	109.2	117.5	104.6	62705	111.01541553	DE
26	-11.4	-9.4137076796	121.1	126.7	100.3	68708	111.69502899	DE
52	6.8	6.60835762877	102.9	126.7	99.7	71795	109.64050259	DE
156	20.92	23.5638657355	88.78	130.7	77	80707	104.20839387	DE
260	4.5	4.27756653992	105.2	130.7	34.2	102962	88.66061812	DE

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
ATOAtos SE	1.73 € (70.78%)	21.57M
ALEUPEuroplasma	0.10 € (62.60%)	7.88M
COCasino Guichard Perrachon	1.80 € (58.23%)	2.02M
ALSPWSpineway	0.1282 € (56.72%)	5.87M
ALNEVNeovacs	0.0003 € (50.00%)	202.1M
GJAJGroupe Jaj	0.60 € (-43.93%)	300
ALIMOGroupimo	0.189 € (-30.51%)	53
ALNMRNamR SA	0.548 € (-19.41%)	11.74k
BUIBarbara Bui	5.85 € (-18.75%)	19
MLCMIScemi	3.46 € (-13.50%)	466
ALNEVNeovacs	0.0003 € (50.00%)	202.1M
ALHPIHopium SA	0.0109 € (19.78%)	63.48M
BCPBanco Comercial Portugues SA	0.4443 € (0.07%)	26.33M
ATOAtos SE	1.73 € (70.78%)	21.57M
LATLatecoere	0.0082 € (10.81%)	14.69M